Markets led today’s AI story, and it wasn’t because model performance suddenly dipped—it was the math. After a Financial Times report said OpenAI’s annualized revenue was about $20 billion lower than previously believed, OpenAI told investors its figure was closer to $50 billion rather than $68 billion. The knock-on effect hit investor confidence across the sector: the Nasdaq fell 1.25%, and related tech stocks slid as traders tried to reconcile the discrepancy, especially the shift from gross to net framing ahead of expected IPO chatter around both OpenAI and Anthropic.
If the financial narrative was about clarity and trust, the funding news was about operational proof. Gallatin AI raised $50 million for its military logistics platform, Navigator, used by U.S. Army and U.S. Air Force customers to manage supply-chain operations. With a Series A following a $15 million seed in 2024, the company is betting that predictive forecasting and automated planning workflows are the kind of AI features budgets can underwrite.
Meanwhile, Samuel King’s AI-designed virus work pushes a different frontier: using generative models to sketch genetic blueprints for microscopic viruses. It’s a reminder that as AI moves from automating tasks to proposing biological designs, the next debates will be as much about governance and biosafety as they are about capability.
